Geode Capital Management LLC Has $16.77 Million Holdings in InMode Ltd. (NASDAQ:INMD)

Geode Capital Management LLC reduced its holdings in InMode Ltd. (NASDAQ:INMD - Free Report) by 8.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,003,999 shares of the healthcare company's stock after selling 97,952 shares during the quarter. Geode Capital Management LLC owned 1.44% of InMode worth $16,767,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. raised its position in InMode by 4.4% in the 4th quarter. JPMorgan Chase & Co. now owns 1,084,241 shares of the healthcare company's stock valued at $18,107,000 after buying an additional 45,638 shares during the last quarter. River Road Asset Management LLC acquired a new stake in shares of InMode in the fourth quarter valued at approximately $8,572,000. Yelin Lapidot Holdings Management Ltd. raised its holdings in shares of InMode by 0.6% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 308,852 shares of the healthcare company's stock valued at $5,158,000 after purchasing an additional 1,950 shares during the last quarter. Seizert Capital Partners LLC lifted its position in shares of InMode by 105.2% in the fourth quarter. Seizert Capital Partners LLC now owns 250,627 shares of the healthcare company's stock worth $4,185,000 after purchasing an additional 128,483 shares in the last quarter. Finally, Marathon Asset Management Ltd boosted its holdings in InMode by 57.4% during the fourth quarter. Marathon Asset Management Ltd now owns 182,349 shares of the healthcare company's stock worth $3,045,000 after purchasing an additional 66,475 shares during the last quarter. Institutional investors and hedge funds own 68.04% of the company's stock.

InMode Trading Up 0.6 %

Shares of INMD traded up $0.10 during midday trading on Friday, reaching $16.23. The stock had a trading volume of 166,466 shares, compared to its average volume of 1,170,517. The firm has a market cap of $1.13 billion, a PE ratio of 6.92 and a beta of 1.96. The firm has a 50 day simple moving average of $17.41 and a 200-day simple moving average of $17.61. InMode Ltd. has a one year low of $13.68 and a one year high of $19.85.

Wall Street Analyst Weigh In

INMD has been the topic of several analyst reports. Needham & Company LLC reissued a "hold" rating on shares of InMode in a research report on Wednesday, April 9th. Barclays upped their target price on InMode from $26.00 to $29.00 and gave the stock an "overweight" rating in a report on Wednesday, February 5th. Finally, Jefferies Financial Group decreased their price target on InMode from $16.00 to $15.00 and set a "hold" rating for the company in a research note on Monday, April 14th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $21.25.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.